Hypotensive effect of atorvastatin is not related to changes in inflammation and oxidative stress.
Journal Title: Pharmacological Reports - Year 2010, Vol 62, Issue 5
Abstract
We sought to determine if atorvastatin lowers blood pressure in patients with previously diagnosed and well-controlled essential arterial hypertension and if this effect could be related to anti-inflammatory and anti-oxidative effects. Among 92 patients with essential arterial hypertension, we studied 56 non-smoking and normolipemic: 39 were randomized to receive 80 mg atorvastatin daily for 3 months (statin-treated patients, ST), and the rest continued a previous hypotensive therapy (statin-free patients, SF). Blood pressure was measured using a 24-h ambulatory blood pressure measurement device. Serum levels of high-sensitivity C-reactive protein (hs-CRP), total antioxidant status (TAS) and plasma peroxides (assessed by Oxystat) were measured in both groups. The mean change in systolic BP (SBP) for atorvastatin was -5.7 mmHg (95% confidence interval CI, -4.1 to -7.2 mmHg), and the mean change in diastolic BP (DBP) was -3.9 mmHg (95% CI, -2.7 to -5.0 mmHg). No change in BP in SF patients was observed. In the ST group, hs-CRP and peroxides did not significantly decrease. In the SF group, concentrations of hs-CRP proceeded to decrease while peroxides increased. In the ST group, changes in hs-CRP correlated with changes in total cholesterol and low-density lipoprotein cholesterol (r = 0.41, p = 0.013 and r = 0.35, p = 0.04, respectively) but did not correlate with changes in BP. The hypotensive statin effect was independent of the hypolipemic effect. During three months of observation, TAS concentrations in both groups remained stable. In this randomized study, additionally administered atorvastatin to non-smoking and normolipemic patients with well-controlled essential arterial hypertension resulted in reduction of BP. This effect was not followed by significant changes in hs-CRP, TAS or Oxystat concentrations. The hypotensive effect of atorvastatin did not depend on anti-inflammatory, anti-oxidative or hypolipemic actions.
Authors and Affiliations
Agnieszka Kuklińska, Barbara Mroczko, Włodzimierz Musiał, Robert Sawicki, Anna Kozieradzka, Monika Usowicz-Szaryńska, Karol Kamiński, Małgorzata Knapp, Maciej Szmitkowski
Keywords
Related Articles
- EP ID EP107930
- DOI -
- Views 90
- Downloads 0
Age-related macular degeneration (AMD): pathogenesis and therapy.
Age-related macular degeneration (AMD) is a disease leading to severe visual loss and legal blindness in the elderly population. Its pathogenesis, likely multifactorial, involving a complex interaction of metabolic, func...
Cyclooxygenase inhibitors: a novel direction for Alzheimer's management.
Research in Alzheimer's disease (AD) currently includes various cellular, molecular, genetic, clinical and therapeutic approaches. The cytopathological significance of oxidative damage has been studied in neurons of AD p...
Eplerenone promotes alternative activation in human monocyte-derived macrophages.
Background: In this study, we have analyzed the response of human monocyte-derived macrophages to mineralocorticoid axis modulators. Methods: Human monocyte-derived macrophages were incubated with aldosterone alone, eple...
Potential hepato-protective effect of α-tocopherol or simvastatin in aged rats.
Background: The effect of α-tocopherol or simvastatin treatment on antioxidant defense in liver of old rats was investigated. Methods: Endogenous thiobarbituric acid reactive substances (TBARS) and total nitrite/nitrate...
Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population.
P-glycoprotein (P-gp), the product of MDR1 gene, is a protein which mediates transmembrane transport of a great number of xenobiotics including cyclosporin A used as an immunosuppressive drug in patients with allogenic k...